(VIANEWS) – IPSEN (IPN.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Drug Manufacturers—Specialty & Generic industry.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| IPSEN (IPN.PA) | €110.30 | 1.04% | 17.91% |
| VETOQUINOL (VETO.PA) | €99.50 | 0.98% | 8.99% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. IPSEN (IPN.PA)
1.04% Forward Dividend Yield and 17.91% Return On Equity
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Earnings Per Share
As for profitability, IPSEN has a trailing twelve months EPS of €7.4.
PE Ratio
IPSEN has a trailing twelve months price to earnings ratio of 14.91. Meaning, the purchaser of the share is investing €14.91 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.91%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.9%, now sitting on 3.44B for the twelve trailing months.
More news about IPSEN.
2. VETOQUINOL (VETO.PA)
0.98% Forward Dividend Yield and 8.99% Return On Equity
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
Earnings Per Share
As for profitability, VETOQUINOL has a trailing twelve months EPS of €4.97.
PE Ratio
VETOQUINOL has a trailing twelve months price to earnings ratio of 20.02. Meaning, the purchaser of the share is investing €20.02 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.99%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VETOQUINOL’s stock is considered to be overbought (>=80).
Volatility
VETOQUINOL’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.16%, a positive 0.22%, and a positive 1.39%.
VETOQUINOL’s highest amplitude of average volatility was 0.47% (last week), 1.02% (last month), and 1.39% (last quarter).
Moving Average
VETOQUINOL’s worth is way above its 50-day moving average of €90.28 and higher than its 200-day moving average of €97.60.
More news about VETOQUINOL.
